Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : wla(warner lambert) -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (865)	7/16/1999 3:58:00 PM
From: Anthony Wong	Respond to of 942

Takeda Wins U.S. FDA Approval for Actos Diabetes Pill (Update3) Bloomberg News July 16, 1999, 10:11 a.m. ET Takeda Wins U.S. FDA Approval for Actos Diabetes Pill (Update3) (Adds analyst comment, details on drug label, U.S. share activity.) Tokyo, July 16 (Bloomberg) -- Takeda Chemical Industries Ltd.'s Actos diabetes pill won approval of the U.S. Food and Drug Administration, setting up a battle between Actos and SmithKline Beecham Plc's Avandia for a market worth billions of dollars. Actos and Avandia each are expected to generate more than $1 billion in peak annual sales, leapfrogging Warner-Lambert Co.'s Rezulin, which has been linked to more than 30 deaths and been dogged by FDA warnings about liver problems. Doctors and analysts say both Actos and Avandia appear to lack Rezulin's dangerous side effects, though analysts expect Actos's easier dosing regimen and broader approval will give it an edge in the growing market for adult onset, or Type II, diabetes. Analysts expect that market to grow to $5 billion a year. ''It gives an advantage to Actos, but I think there is a enough market that they both can become big drugs,'' said Mehta Partners analyst Sergio Traversa, who said he expects both drugs to be multibillion dollar sellers. ''There is room for Avandia, too.'' Actos, which likely will go on sale early next month, and Avandia, which went on sale in June, are from the same class of drugs and are licensed for use alone or with Bristol-Myers Squibb Co.'s Glucophage, the world's best selling non-insulin diabetes drug. Chemically Similar Though chemically similar, Actos may have advantages over Avandia in a few areas. Actos doesn't appear to raise cholesterol level, as Avandia seem to do, and Actos is a true once-a-day pill, while Avandia may need to be taken twice a day. In addition, Actos has been approved for use alone, with Glucophage, with insulin and with widely used sulfonylurea drugs, including Pfizer Inc.'s Glucotrol and Diabinese, and Pharmacia & Upjohn Inc.'s Micronase and Orinase. Avandia lacks the insulin and sulfonylurea uses. ''It's a big positive factor for Takeda that Actos can be used with sulfonylurea drugs,'' said Kazuhisa Sugita, a senior analyst at ABN Amro Securities (Japan) Ltd., who rates Takeda ''outperform.'' SmithKline, which announced the approval of Avandia May 25, placed its drug on pharmacy shelves within weeks to secure a headstart against Actos. Already Avandia is eating into Rezulin prescriptions, which generated $748 million in 1998 sales. Traversa said he expects that the availability of both Actos and Avandia will severely limit Rezulin sales, though he said it was unlikely that the drug's decline would be sudden. ''I think it will be a stable decline,'' he said, adding that doctors won't necessarily move successful Rezulin patients to another drug. Takeda will co-market its drug with Eli Lilly & Co., which is credited with pioneering the development of insulin in the 1920s. SmithKline has paired with Bristol-Myers to sell Avandia. The value of the U.S. market for all diabetes drugs was about $2 billion in 1998, said Shinji Honda, a Takeda spokesman. Actos users will have to take liver tests every two months in the first year, a caution prompted by the chemical similarity of Actos and Avandia to Rezulin. Takeda shares declined 150 yen to 6,040 in trading on the Tokyo exchange. Lilly shares rose 5/16 to 77 3/8 in early U.S. trading. SmithKline's American depositary receipts rose 3/4 to 65 1/8.